A Phase 1 interventional study of Biopsy Procedure and Biospecimen Collection in Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma and Platinum-Resistant Lung Small Cell Carcinoma, sponsored by National Cancer Institute (NCI). Terminated at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by National Cancer Institute (NCI) · Phase 1, Interventional, and Treatment
How we know · 10 judgments · 2 readings being read again
Withdrawal of tazemetostat supply led to early study closure.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Small Cell Lung Carcinoma by National Cancer Institute (NCI) — 5 open to participants now, 15 under way, none of them phase 3. Small Cell Lung Carcinoma · National Cancer Institute (NCI).
Among the 65 studies in Small Cell Lung Carcinoma by National Cancer Institute (NCI), this one is the 40th largest by enrollment of the 55 interventional ones that give a count, is the only one that started in 2022, is one of 20 in phase 1, and was the 60th registered.
1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.
Browse Small Cell Lung Carcinoma studies →5 of the 65 studies in Small Cell Lung Carcinoma by National Cancer Institute (NCI) are open now, in 1 country. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
National Cancer Institute (NCI) · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 265 Small Cell Lung Carcinoma studies recruiting now, 176 (66%) set no upper age limit and 65 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 40 · Phase 3 1
First in 1995; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 56 across 1,079 interventional studies indexed under Small Cell Lung Carcinoma.
Median enrollment 40 across the 55 interventional studies, 1,600 across the 3 observational. Of the 48 that completed or were terminated, 25 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 335 are open to participants now.
Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.
3 of the studies in Small Cell Lung Carcinoma by National Cancer Institute (NCI) that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06066138National Cancer Institute (NCI)A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | 2027-01-31 |
| NCT04314401National Cancer Institute (NCI)National Cancer Institute "Cancer Moonshot Biobank" | 2027-04-30 |
| NCT06228066National Cancer Institute (NCI)Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER) | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 65 studies in Small Cell Lung Carcinoma by National Cancer Institute (NCI), from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase I trial tests the safety, side effects, and best dose of tazemetostat in combination with topotecan and pembrolizumab in treating patients with small cell lung cancer that has come back after a period of improvement (recurrent). Tazemetostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tazemetostat in combination with topotecan and pembrolizumab may shrink or stabilize recurrent small cell lung cancer.
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose (MTD) of tazemetostat hydrobromide (tazemetostat) in combination with topotecan hydrochloride (topotecan) and pembrolizumab in patients with recurrent extensive stage (ES)-small cell lung cancer (SCLC), by reviewing dose-limiting toxicities (DLTs) in cycle 1 (21 days). (Dose-Escalation Cohort) II. To select the recommended phase II dose (RP2D) for a combination of tazemetostat, topotecan and pembrolizumab, based on pharmacodynamic (PD) parameters as well as overall efficacy and tolerability. (Dose-Escalation Cohort) III. To evaluate safety and tolerability of tazemetostat in combination with topotecan and pembrolizumab. (Expansion Cohort)
SECONDARY OBJECTIVES:
I. To observe and record anti-tumor activity. II. To determine in a very preliminary fashion, the efficacy of a combination of tazemetostat, topotecan and pembrolizumab in recurrent ES-SCLC by assessing overall response rate (ORR), progression-free survival (PFS), duration of response (DOR) and overall survival (OS).
EXPLORATORY OBJECTIVES:
I. To perform molecular profiling assays on malignant and normal tissues, including, but not limited to ribonucleic acid (RNA) sequencing (RNA-Seq).
II. To assess modulation of EZH2 targets including SLFN11 and MHC among others. III. To identify potential predictive biomarkers of response. IV. To identify mechanisms of drug sensitivity and resistance using deoxyribonucleic acid (DNA)- and RNA-based assessment platforms.
V. To contribute genetic analysis data from de-identified biospecimens to Genomic Data Commons (GDC), a well annotated cancer molecular and clinical data repository, for current and future research; specimens will be annotated with key clinical data, including presentation, diagnosis, staging, summary treatment, and if possible, outcome.
VI. To bank formalin-fixed, paraffin-embedded (FFPE) tissue, blood (for cell-free DNA analysis), and nucleic acids obtained from patients at the Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) at Nationwide Children's Hospital.
VII. To characterize circulating cell-free DNA (cfDNA).
OUTLINE: This is a dose-escalation study of tazemetostat followed by a dose-expansion study.
Patients receive tazemetostat orally (PO) twice daily (BID) for 7 days prior to cycle 1 and then on days 1-21 of each cycle, pembrolizumab intravenously (IV) over 30 minutes on day 1 of each cycle, and topotecan IV over 30 minutes on days 1-3 or days 1-5 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) scan throughout the study and undergo biopsy and collection of blood on study.
After completion of study treatment, patients are followed every 3 months after removal from study treatment until study closure or death, whichever occurs first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Creatinine =\< 1.5 institutional ULN OR (GFR) >= 60 mL/min/1.73 m\^2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m\^2
Exclusion Criteria:
Patients who have had chemotherapy, , or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study.
Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive tazemetostat PO BID for 7 days prior to cycle 1 and then on days 1-21 of each cycle, pembrolizumab IV over 30 minutes on day 1 of each cycle, and topotecan IV over 30 minutes on days 1-3 or days 1-5 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan throughout the study and undergo biopsy and collection of blood on study.
Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Biological: Pembrolizumab · Drug: Tazemetostat Hydrobromide · Drug: Topotecan Hydrochloride
Undergo biopsy
Also known as: Biopsy, BIOPSY_TYPE, Bx
Undergo collection of blood
Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection
Undergo CT scan
Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography
Given IV
Also known as: BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, Pembrolizumab Biosimilar SB27, QL2107, RPH 075, RPH-075, RPH075, SB 27, SB-27, SB27, SCH 900475, SCH-900475, SCH900475
Given PO
Also known as: EPZ-6438 Monohydrobromide, Tazemetostat Monohydrobromide, TAZVERIK
Given IV
Also known as: Evotopin, Hycamptamine, Hycamtin, Nogitecan Hydrochloride, Potactasol, SKF S 104864 A, SKF S-104864-A, SKF S104864A, Topotec, Topotecan HCl, topotecan hydrochloride (oral)
Maximum Tolerated Dose (Dose-escalation Cohort) of Tazemetostat in Combination With Topotecan and Pembrolizumab
Maximum tolerated dose (MTD) is the highest dose level with observed toxicity rate less than 33%.
Time frame: Up to 21 days (cycle 1)
Incidence of Adverse Events (Expansion Cohort) by Type and Grade in the Expansion Cohort
The incidence of adverse events will be reported by type and grade, for the participants in the expansion cohort. Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 1 is mild. Grade 2 is moderate. Grade 3 is serious. Grade 4 is life-threatening. Grade 5 is death related to adverse event.
Time frame: Up to 3 years
Incidence of Grade 3 or Above Adverse Events by Type Related or Possibly Related to Study Treatment in the Dose Escalation Cohort
Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 1 is mild. Grade 2 is moderate. Grade 3 is serious. Grade 4 is life-threatening. Grade 5 is death related to adverse event.
Time frame: Start of treatment through 30 days post last dose, an average of 112.33 days or 3.22 months
Overall Response Rate (ORR) (Expansion Cohort)
ORR will be estimated based on participants evaluable for response and will be presented along with a 95% confidence interval. ORR was assessed by the Immune Related Response Evaluation Criteria in Solid Tumors (iRECIST) criteria. Complete Response (CR) is disappearance of all target lesions. Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Progressive Disease (PD) is at least a 20% increase in the sum of diameters of target lesions.
Time frame: Up to 3 years
Progression-free Survival (PFS) (Expansion Cohort)
PFS will be estimated using the Kaplan-Meier method, resulting in median survival times with 95% confidence interval. PFS is defined as the duration of time from start of treatment to time of progression or death. PFS was assessed by the Immune Related Response Evaluation Criteria in Solid Tumors (iRECIST) criteria. Progression is defined as at least 1 20% increase in the sum of the diameters of target lesions. Appearance of one or more new lesions is also progression.
Time frame: From the on-study date until the date of progression or death without progression, assessed up to 3 years
Overall Survival (OS) (Expansion Cohort)
OS will be estimated using the Kaplan-Meier method, resulting in median survival times with 95% confidence interval. OS is determined from the on-study date until the date of death without progression. Progression was assessed by the Immune Related Response Evaluation Criteria in Solid Tumors (iRECIST) criteria and is defined as at least a 20% increase in the sum of the diameters of target lesions. Appearance of one or more new lesions is also progression.
Time frame: From the on-study date until the date of death or last follow-up, assessed up to 3 years
Duration of Response (DOR) (Expansion Cohort)
DOR will be estimated using the Kaplan-Meier method, resulting in median survival times with 95% confidence interval. DOR is calculated from the first date of response to the date of progression. Response was assessed by the Immune Related Response Evaluation Criteria in Solid Tumors (iRECIST) criteria. Progression is defined as at least a 20% increase in the sum of the diameters of target lesions. Appearance of one or more new lesions is also progression.
Time frame: From the first date of response to the date of progression, assessed up to 3 years
Gene Expression Estimated by the Ribonucleic Acid (RNA) Sequencing in Participants With Recurrent Extensive Stage Small Cell Lung Cancer (ES-SCLC) (Dose Expansion)
RNA Seq molecular profiling will be performed on malignant and normal tissue obtained by biopsy.
Time frame: Baseline, post Tazemetostat (Day 1 Cycle 1/(1 cycle =21 days), and post 3-drug combination
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v50). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
Time frame: From the first study intervention, Study Day 1 of Cycle 1 through 30 days after the study agent (s) was/were administered, an average of 112.33 days or 3.22 months
Number of Participants With a Dose Limiting Toxicity (DLT)
A DLT is the occurrence of any of the following toxicities, if determined by the Investigator to be possibly, probably or definitely related to study drug administration: Grade 4 nonhematologic toxicity (not laboratory), Neutropenia grade 4 for \>7 days, Grade 3 nonhematologic toxicity (not laboratory) lasting \>3 days despite optimal supportive care, Any grade 3 or 4 nonhematologic laboratory value if medical intervention is required, the abnormality leads to a hospitalization, or the abnormality persists for \>1 week. Febrile neutropenia Grade 3 or Grade 4, Thrombocytopenia \<25,000/mm\^3 if associated with a bleeding event which does not result in hemodynamic instability but requires an elective platelet transfusion, or a life-threatening bleeding event which results in urgent intervention and admission to an Intensive Care Unit. Prolonged delay (.2 weeks) in starting Cycle 2 due to treatment-related toxicity. Grade 5 toxicity.
Time frame: Cycle 1 (21 days)
| Milestone | Dose Escalation, Participants Enrolled But Not Treated | Dose Escalation Arm 1(Induction), Dose Level 1 | Dose Escalation Arm 1(Induction) Dose Level -2 | Dose Escalation Arm 1(Induction, Followed by Arm 2 (21-day Cycles) Dose Level 1 | Dose Escalation Arm 1(Induction), Followed by Arm 2 (21-day Cycles) Dose Level 1 Then Dose Level -1 | Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -2 | Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -1 |
|---|---|---|---|---|---|---|---|
| Started | 4 | 1 | 1 | 6 | 1 | 5 | 4 |
| 7-day induction tazemetostat twice a day (bid) (7 days(d) prior to cycle(c) 1 day 1) | 0 | 1 | 1 | 6 | 1 | 5 | 4 |
| Completed | 0 | 1 | 1 | 6 | 1 | 5 | 4 |
| Not completed | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Screen failures | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Dose Escalation, Participants Enrolled But Not Treated | Dose Escalation Arm 1(Induction), Dose Level 1 | Dose Escalation Arm 1(Induction) Dose Level -2 | Dose Escalation Arm 1(Induction, Followed by Arm 2 (21-day Cycles) Dose Level 1 | Dose Escalation Arm 1(Induction), Followed by Arm 2 (21-day Cycles) Dose Level 1 Then Dose Level -1 | Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -2 | Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -1 |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 6 | 1 | 5 | 4 |
| 21-day cycles tazemetostat bid (d1 to d21) + topotecan (d1 to d3 or d1 to d5) + pembrolizumab (d1) | 0 | 0 | 0 | 6 | 1 | 5 | 4 |
| Completed | 0 | 0 | 0 | 5 | 1 | 5 | 4 |
| Not completed | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Maximum tolerated dose (MTD) is the highest dose level with observed toxicity rate less than 33%.
| mg/m^2 | All Participants in the Dose Escalation Cohort |
|---|---|
| Maximum Tolerated Dose (Dose-escalation Cohort) of Tazemetostat in Combination With Topotecan and Pembrolizumab | NA |
The incidence of adverse events will be reported by type and grade, for the participants in the expansion cohort. Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 1 is mild. Grade 2 is moderate. Grade 3 is serious. Grade 4 is life-threatening. Grade 5 is death related to adverse event.
No measurements were reported for this outcome.
Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 1 is mild. Grade 2 is moderate. Grade 3 is serious. Grade 4 is life-threatening. Grade 5 is death related to adverse event.
| Adverse events | Dose Escalation, Participants Enrolled But Not Treated | Dose Escalation Arm 1(Induction), Dose Level 1 | Dose Escalation Arm 1(Induction) Dose Level -2 | Dose Escalation Arm 1(Induction, Followed by Arm 2 (21-day Cycles) Dose Level 1 | Dose Escalation Arm 1(Induction), Followed by Arm 2 (21-day Cycles) Dose Level 1 Then Dose Level -1 | Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -2 | Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -1 |
|---|---|---|---|---|---|---|---|
| Grade 3 Allergic Reaction | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Grade 3 Anemia | 0 | 0 | 0 | 4 | 2 | 0 | 6 |
| Grade 3 GI Bleed | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Grade 3 Hypotension | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Grade 3 Infusion Related Reaction | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Grade 3 Lymphocyte Count Decreased | 0 | 0 | 0 | 1 | 1 | 2 | 1 |
| Grade 3 Neutrophil Count Decreased | 0 | 0 | 0 | 5 | 1 | 0 | 2 |
| Grade 3 Paresthesia | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Grade 3 Platelet Count Decreased | 0 | 0 | 0 | 2 | 2 | 0 | 1 |
| Grade 3 White Blood Cell Count Decreased | 0 | 0 | 0 | 3 | 3 | 0 | 0 |
| Grade 4 Delirium | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Grade 4 Dyspnea | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Grade 4 Lymphocyte Count Decreased | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Grade 4 Neutrophil Count Decreased | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Grade 4 Platelet Count Decreased | 0 | 0 | 0 | 2 | 2 | 0 | 1 |
| Grade 4 White Blood Cell Count Decreased | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Any Grade 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ORR will be estimated based on participants evaluable for response and will be presented along with a 95% confidence interval. ORR was assessed by the Immune Related Response Evaluation Criteria in Solid Tumors (iRECIST) criteria. Complete Response (CR) is disappearance of all target lesions. Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Progressive Disease (PD) is at least a 20% increase in the sum of diameters of target lesions.
No measurements were reported for this outcome.
PFS will be estimated using the Kaplan-Meier method, resulting in median survival times with 95% confidence interval. PFS is defined as the duration of time from start of treatment to time of progression or death. PFS was assessed by the Immune Related Response Evaluation Criteria in Solid Tumors (iRECIST) criteria. Progression is defined as at least 1 20% increase in the sum of the diameters of target lesions. Appearance of one or more new lesions is also progression.
No measurements were reported for this outcome.
OS will be estimated using the Kaplan-Meier method, resulting in median survival times with 95% confidence interval. OS is determined from the on-study date until the date of death without progression. Progression was assessed by the Immune Related Response Evaluation Criteria in Solid Tumors (iRECIST) criteria and is defined as at least a 20% increase in the sum of the diameters of target lesions. Appearance of one or more new lesions is also progression.
No measurements were reported for this outcome.
DOR will be estimated using the Kaplan-Meier method, resulting in median survival times with 95% confidence interval. DOR is calculated from the first date of response to the date of progression. Response was assessed by the Immune Related Response Evaluation Criteria in Solid Tumors (iRECIST) criteria. Progression is defined as at least a 20% increase in the sum of the diameters of target lesions. Appearance of one or more new lesions is also progression.
No measurements were reported for this outcome.
RNA Seq molecular profiling will be performed on malignant and normal tissue obtained by biopsy.
No measurements were reported for this outcome.
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v50). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
| Participants | Dose Escalation, Participants Enrolled But Not Treated | Dose Escalation Arm 1(Induction), Dose Level 1 | Dose Escalation Arm 1(Induction) Dose Level -2 | Dose Escalation Arm 1(Induction, Followed by Arm 2 (21-day Cycles) Dose Level 1 | Dose Escalation Arm 1(Induction), Followed by Arm 2 (21-day Cycles) Dose Level 1 Then Dose Level -1 | Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -2 | Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -1 |
|---|---|---|---|---|---|---|---|
| Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 0 | 1 | 1 | 6 | 1 | 5 | 4 |
A DLT is the occurrence of any of the following toxicities, if determined by the Investigator to be possibly, probably or definitely related to study drug administration: Grade 4 nonhematologic toxicity (not laboratory), Neutropenia grade 4 for \>7 days, Grade 3 nonhematologic toxicity (not laboratory) lasting \>3 days despite optimal supportive care, Any grade 3 or 4 nonhematologic laboratory value if medical intervention is required, the abnormality leads to a hospitalization, or the abnormality persists for \>1 week. Febrile neutropenia Grade 3 or Grade 4, Thrombocytopenia \<25,000/mm\^3 if associated with a bleeding event which does not result in hemodynamic instability but requires an elective platelet transfusion, or a life-threatening bleeding event which results in urgent intervention and admission to an Intensive Care Unit. Prolonged delay (.2 weeks) in starting Cycle 2 due to treatment-related toxicity. Grade 5 toxicity.
| Participants | Dose Escalation, Participants Enrolled But Not Treated | Dose Escalation Arm 1(Induction), Dose Level 1 | Dose Escalation Arm 1(Induction) Dose Level -2 | Dose Escalation Arm 1(Induction, Followed by Arm 2 (21-day Cycles) Dose Level 1 | Dose Escalation Arm 1(Induction), Followed by Arm 2 (21-day Cycles) Dose Level 1 Then Dose Level -1 | Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -2 | Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -1 |
|---|---|---|---|---|---|---|---|
| Number of Participants With a Dose Limiting Toxicity (DLT) | 0 | 1 | 0 | 2 | 1 | 0 | 1 |
Collected over All-Cause Mortality was monitored/assessed a median of 5.68 months (range 1.08-37.15 months). Adverse Events were monitored/assessed from the first study intervention, Study Day 1 of Cycle 1 through 30 days after the study agent (s) was/were administered, an average of 3.22 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Escalation, Participants Enrolled But Not Treated | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Dose Escalation Arm 1(Induction), Dose Level 1 | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) |
| Dose Escalation Arm 1(Induction) Dose Level -2 | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Dose Escalation Arm 1(Induction, Followed by Arm 2 (21-day Cycles) Dose Level 1 | 5/6 (83.3%) | 5/6 (83.3%) | 6/6 (100%) |
| Dose Escalation Arm 1(Induction), Followed by Arm 2 (21-day Cycles) Dose Level 1 Then Dose Level -1 | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) |
| Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -2 | 3/5 (60%) | 2/5 (40%) | 5/5 (100%) |
| Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -1 | 3/4 (75%) | 3/4 (75%) | 4/4 (100%) |
| Event | Dose Escalation, Participants Enrolled But Not Treated | Dose Escalation Arm 1(Induction), Dose Level 1 | Dose Escalation Arm 1(Induction) Dose Level -2 | Dose Escalation Arm 1(Induction, Followed by Arm 2 (21-day Cycles) Dose Level 1 | Dose Escalation Arm 1(Induction), Followed by Arm 2 (21-day Cycles) Dose Level 1 Then Dose Level -1 | Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -2 | Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -1 |
|---|---|---|---|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 0/4 | 1/1 | 0/1 | 0/6 | 0/1 | 1/5 | 0/4 |
| Alkaline phosphatase increasedInvestigations | 0/4 | 1/1 | 0/1 | 0/6 | 0/1 | 1/5 | 0/4 |
| Aspartate aminotransferase increasedInvestigations | 0/4 | 1/1 | 0/1 | 0/6 | 0/1 | 1/5 | 0/4 |
| Blood bilirubin increasedInvestigations | 0/4 | 1/1 | 0/1 | 1/6 | 0/1 | 1/5 | 0/4 |
| Death NOSGeneral disorders | 0/4 | 1/1 | 0/1 | 0/6 | 0/1 | 0/5 | 0/4 |
| Platelet count decreasedInvestigations | 0/4 | 0/1 | 0/1 | 1/6 | 1/1 | 0/5 | 1/4 |
| AnemiaBlood and lymphatic system disorders | 0/4 | 0/1 | 0/1 | 1/6 | 0/1 | 0/5 | 2/4 |
| Back painMusculoskeletal and connective tissue disorders | 0/4 | 0/1 | 0/1 | 0/6 | 0/1 | 0/5 | 1/4 |
| FallInjury, poisoning and procedural complications | 0/4 | 0/1 | 0/1 | 0/6 | 0/1 | 0/5 | 1/4 |
| Gastric hemorrhageGastrointestinal disorders | 0/4 | 0/1 | 0/1 | 0/6 | 0/1 | 0/5 | 1/4 |
| Event | Dose Escalation, Participants Enrolled But Not Treated | Dose Escalation Arm 1(Induction), Dose Level 1 | Dose Escalation Arm 1(Induction) Dose Level -2 | Dose Escalation Arm 1(Induction, Followed by Arm 2 (21-day Cycles) Dose Level 1 | Dose Escalation Arm 1(Induction), Followed by Arm 2 (21-day Cycles) Dose Level 1 Then Dose Level -1 | Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -2 | Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -1 |
|---|---|---|---|---|---|---|---|
| Activated partial thromboplastin time prolongedInvestigations | 0/4 | 0/1 | 0/1 | 0/6 | 1/1 | 0/5 | 1/4 |
| Alanine aminotransferase increasedInvestigations | 0/4 | 1/1 | 0/1 | 2/6 | 0/1 | 0/5 | 1/4 |
| AnemiaBlood and lymphatic system disorders | 0/4 | 1/1 | 0/1 | 6/6 | 1/1 | 1/5 | 2/4 |
| AnorexiaMetabolism and nutrition disorders | 0/4 | 1/1 | 0/1 | 1/6 | 0/1 | 2/5 | 1/4 |
| Aspartate aminotransferase increasedInvestigations | 0/4 | 1/1 | 0/1 | 2/6 | 0/1 | 0/5 | 2/4 |
| Blood bilirubin increasedInvestigations | 0/4 | 1/1 | 0/1 | 0/6 | 0/1 | 1/5 | 1/4 |
| Bone painMusculoskeletal and connective tissue disorders | 0/4 | 1/1 | 0/1 | 0/6 | 0/1 | 0/5 | 0/4 |
| BruisingInjury, poisoning and procedural complications | 0/4 | 0/1 | 0/1 | 0/6 | 1/1 | 0/5 | 1/4 |
| ChillsGeneral disorders | 0/4 | 0/1 | 0/1 | 0/6 | 1/1 | 1/5 | 0/4 |
| CholecystitisHepatobiliary disorders | 0/4 | 1/1 | 0/1 | 0/6 | 0/1 | 0/5 | 0/4 |
All participants that were enrolled, consented and had data collected are reported in the table.
| Age, Categorical(Participants) | Dose Escalation, Participants Enrolled But Not Treated | Dose Escalation Arm 1(Induction), Dose Level 1 | Dose Escalation Arm 1(Induction) Dose Level -2 | Dose Escalation Arm 1(Induction, Followed by Arm 2 (21-day Cycles) Dose Level 1 | Dose Escalation Arm 1(Induction), Followed by Arm 2 (21-day Cycles) Dose Level 1 Then Dose Level -1 | Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -2 | Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -1 | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 1 | 1 | 2 | 1 | 3 | 1 | 12 |
| >=65 years | 1 | 0 | 0 | 4 | 0 | 2 | 3 | 10 |
| Age, Continuous(years) | Dose Escalation, Participants Enrolled But Not Treated | Dose Escalation Arm 1(Induction), Dose Level 1 | Dose Escalation Arm 1(Induction) Dose Level -2 | Dose Escalation Arm 1(Induction, Followed by Arm 2 (21-day Cycles) Dose Level 1 | Dose Escalation Arm 1(Induction), Followed by Arm 2 (21-day Cycles) Dose Level 1 Then Dose Level -1 | Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -2 | Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -1 | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 59.5 ± 8.58 | 52 | 62 | 67.83 ± 10.74 | 62 | 59.8 ± 14.86 | 68.75 ± 8.02 | 63.41 ± 10.61 |
| Sex: Female, Male(Participants) | Dose Escalation, Participants Enrolled But Not Treated | Dose Escalation Arm 1(Induction), Dose Level 1 | Dose Escalation Arm 1(Induction) Dose Level -2 | Dose Escalation Arm 1(Induction, Followed by Arm 2 (21-day Cycles) Dose Level 1 | Dose Escalation Arm 1(Induction), Followed by Arm 2 (21-day Cycles) Dose Level 1 Then Dose Level -1 | Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -2 | Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -1 | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 3 | 0 | 1 | 3 | 1 | 3 | 3 | 14 |
| Male | 1 | 1 | 0 | 3 | 0 | 2 | 1 | 8 |
| Ethnicity (NIH/OMB)(Participants) | Dose Escalation, Participants Enrolled But Not Treated | Dose Escalation Arm 1(Induction), Dose Level 1 | Dose Escalation Arm 1(Induction) Dose Level -2 | Dose Escalation Arm 1(Induction, Followed by Arm 2 (21-day Cycles) Dose Level 1 | Dose Escalation Arm 1(Induction), Followed by Arm 2 (21-day Cycles) Dose Level 1 Then Dose Level -1 | Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -2 | Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -1 | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Not Hispanic or Latino | 3 | 1 | 1 | 6 | 1 | 5 | 4 | 21 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Dose Escalation, Participants Enrolled But Not Treated | Dose Escalation Arm 1(Induction), Dose Level 1 | Dose Escalation Arm 1(Induction) Dose Level -2 | Dose Escalation Arm 1(Induction, Followed by Arm 2 (21-day Cycles) Dose Level 1 | Dose Escalation Arm 1(Induction), Followed by Arm 2 (21-day Cycles) Dose Level 1 Then Dose Level -1 | Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -2 | Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -1 | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 3 | 1 | 1 | 4 | 1 | 5 | 4 | 19 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Region of Enrollment(participants) | Dose Escalation, Participants Enrolled But Not Treated | Dose Escalation Arm 1(Induction), Dose Level 1 | Dose Escalation Arm 1(Induction) Dose Level -2 | Dose Escalation Arm 1(Induction, Followed by Arm 2 (21-day Cycles) Dose Level 1 | Dose Escalation Arm 1(Induction), Followed by Arm 2 (21-day Cycles) Dose Level 1 Then Dose Level -1 | Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -2 | Dose Escalation Arm 1(Induction) Followed by Arm 2 (21-day Cycles) Dose Level -1 | Total |
|---|---|---|---|---|---|---|---|---|
| United States | 4 | 1 | 1 | 6 | 1 | 5 | 4 | 22 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — National Cancer Institute (NCI) is committed to sharing data in accordance with National Institutes of Health (NIH) policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will be made available after publication of the primary study results and completion of regulatory and sponsor review and will remain available in accordance with National Institutes of Health (NIH) data-retention and sharing policies.
Access criteria: De-identified individual participant data and supporting documents may be made available to qualified researchers whose proposed use is consistent with the informed consent, applicable laws and regulations, and National Institutes of Health (NIH)/National Cancer Institute (NCI) data-sharing policies. Requests will be reviewed by NCI, and access may require an approved research proposal and data-use agreement.
Data sharing details ↗ · grants.nih.gov
Ran from Jul 2022 to primary completion in Feb 2026, 42 months.
Results were first posted in Nov 2026, 8 months after primary completion.
Completion moved once since we started tracking on Sep 25, 2026: Mar 2027 → Apr 2026, on Nov 10, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Withdrawal of tazemetostat supply led to early study closure.
Withdrawal of tazemetostat supply led to early study closure.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tazemetostat
National Cancer Institute (NCI) →